PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
88.49%
R&D growth 50-75% of AVXL's 124.30%. Bruce Berkowitz would examine spending effectiveness.
34.89%
G&A growth while AVXL reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
77.92%
Other expenses change of 77.92% while AVXL maintains costs. Bruce Berkowitz would investigate efficiency.
59.22%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
59.22%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
77.92%
D&A change of 77.92% while AVXL maintains D&A. Bruce Berkowitz would investigate efficiency.
-37.27%
EBITDA decline while AVXL shows 2.19% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-59.22%
Operating income decline while AVXL shows 2.19% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-87.81%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-272.88%
Pre-tax income decline while AVXL shows 0.96% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-272.88%
Net income decline while AVXL shows 0.96% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-252.38%
EPS decline while AVXL shows 9.09% growth. Joel Greenblatt would examine position.
-313.33%
Diluted EPS decline while AVXL shows 9.09% growth. Joel Greenblatt would examine position.
10.47%
Share count reduction below 50% of AVXL's 3.64%. Michael Burry would check for concerns.
-20.54%
Diluted share reduction while AVXL shows 3.64% change. Joel Greenblatt would examine strategy.